Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II multiple ascending dose open-label safety and efficacy study of the Notch Inhibitor LY3056480 in patients with mild to moderate sensorineural hearing loss

Trial Profile

A phase I/II multiple ascending dose open-label safety and efficacy study of the Notch Inhibitor LY3056480 in patients with mild to moderate sensorineural hearing loss

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LY 3056480 (Primary)
  • Indications Sensorineural hearing loss
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms REGAIN
  • Sponsors Audion Therapeutics
  • Most Recent Events

    • 05 Feb 2019 According to the Audion Therapeutics media release, recruitment for phase II part of the study started in January 2019 and company plans to enroll 40 adult patients in UK, Germany and Greece. Efficacy parameters for this phase are pure tone hearing levels and speech in noise performance.
    • 05 Feb 2019 Positive phase I results presented in the Audion Therapeutics media release.
    • 23 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top